Home » Stocks » HROW

Harrow Health, Inc. (HROW)

Stock Price: $8.56 USD -0.38 (-4.25%)
Updated Jun 11, 2021 4:00 PM EDT - Market closed
Market Cap 227.54M
Revenue (ttm) 52.50M
Net Income (ttm) 9.77M
Shares Out 26.58M
EPS (ttm) 0.37
PE Ratio 22.89
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 11
Last Price $8.56
Previous Close $8.94
Change ($) -0.38
Change (%) -4.25%
Day's Open 8.93
Day's Range 8.53 - 9.11
Day's Volume 126,318
52-Week Range 4.65 - 11.24

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Harrow Health (NASDAQ:HROW) posted a 7.77% decrease in earnings from Q4. Sales, however, increased by 5.81% over the previous quarter to $15.44 million.

1 week ago - Benzinga

NASHVILLE, Tenn., June 01, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the launch of its new...

1 week ago - GlobeNewsWire

Multi-center Retrospective Study Demonstrates Statistically Significant Reduction in Signs and Symptoms of Dry Eye Disease Multi-center Retrospective Study Demonstrates Statistically Significant Reducti...

3 weeks ago - GlobeNewsWire

Shares of Harrow Health (NASDAQ:HROW) were flat in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share increased 102.00% year over year to $0.01, which beat ...

1 month ago - Benzinga

Highlights for First Quarter 2021:

1 month ago - GlobeNewsWire

NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced that the Company has c...

1 month ago - GlobeNewsWire

NASHVILLE, Tenn., May 05, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of an addi...

1 month ago - GlobeNewsWire

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

NASHVILLE, Tenn., April 27, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the firs...

1 month ago - GlobeNewsWire

NASHVILLE, Tenn., April 20, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the closing of its u...

1 month ago - GlobeNewsWire

NASHVILLE, Tenn., April 15, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) (“Harrow Health” or the “Company”), an ophthalmic-focused healthcare company, today announced the pricing of its u...

1 month ago - GlobeNewsWire

NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced it has commenced an underwritten registered public offe...

1 month ago - GlobeNewsWire

NASHVILLE, Tenn., April 14, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced certain preliminary unaudited financial results for the...

1 month ago - GlobeNewsWire

Harrow (HROW) delivered earnings and revenue surprises of -50.00% and 0.73%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

Company's Prior-Quarter Momentum Continues in Fourth Quarter Company's Prior-Quarter Momentum Continues in Fourth Quarter

3 months ago - GlobeNewsWire

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

NASHVILLE, Tenn., Feb. 25, 2021 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW), an ophthalmic-focused healthcare company, today announced that it will release its financial results for the fourt...

3 months ago - GlobeNewsWire

Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021 Company Expects to Begin Phase 2 Clinical Study in the Third Quarter of 2021

4 months ago - GlobeNewsWire

The COVID-19 crisis has drastically transformed the fortune of the medical services industry. The industry has been witnessingsignificant demand for telemedicine-focused online medical services.

Other stocks mentioned: CDNA, BMXMF, AMEH
5 months ago - Zacks Investment Research

Harrow Health (HROW) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.

6 months ago - Zacks Investment Research

NASHVILLE, Tenn., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that a study featuring its patented MKO Melt® formulation has been published in the American Associ...

6 months ago - GlobeNewsWire

NASHVILLE, Tenn., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that Mark Baum, Harrow's Chief Executive Officer, and Andrew Boll, Harrow's Chief Financial Officer...

6 months ago - GlobeNewsWire

Harrow Health, Inc. (HROW) CEO Mark Baum on Q3 2020 Results - Earnings Call Transcript

7 months ago - Seeking Alpha

Harrow (HROW) delivered earnings and revenue surprises of 88.24% and 65.89%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

7 months ago - Zacks Investment Research

NASHVILLE, Tenn., Nov. 09, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today reported results for the third quarter 2020. Please click here to review Harrow Health's Letter to S tockhold...

7 months ago - GlobeNewsWire

Harrow Health (NASDAQ: HROW) will be releasing its next round of earnings this Monday, November 09. For all of the relevant information, here is your guide for Monday's Q3 earnings announcement.

7 months ago - Benzinga

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

NASHVILLE, Tenn., Oct. 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, November 9, 2020, it will release third quarter 2020 fin...

7 months ago - GlobeNewsWire

Harrow Health has been on a bit of a cold streak lately, but there might be light at the end of the tunnel for this overlooked stock.

7 months ago - Zacks Investment Research

NASHVILLE, Tenn., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Larry Van Horn to its Board of Directors.

8 months ago - GlobeNewsWire

As of late, it has definitely been a great time to be an investor Harrow Health.

8 months ago - Zacks Investment Research

NASHVILLE, Tenn., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it will be attending Lake Street’s 4th Annual Best Ideas Growth (BIG4) Conference September...

9 months ago - GlobeNewsWire

Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2020 Results - Earnings Call Transcript

10 months ago - Seeking Alpha

Harrow (HROW) delivered earnings and revenue surprises of 80.00% and 36.61%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

On Monday, August 10, Harrow Health (NASDAQ: HROW) will release its latest earnings report.

10 months ago - Benzinga

Harrow (HROW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

10 months ago - Zacks Investment Research

NASHVILLE, Tenn., July 27, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that after the close of trading on Monday, August 10, 2020, it will release second quarter 2020 f...

10 months ago - GlobeNewsWire

The study published in Clinical Ophthalmology shows equivalent clinical outcomes to separately dosed eyedrops and a strong patient preference for the ImprimisRx proprietary combination drop therapy for ...

10 months ago - GlobeNewsWire

NASHVILLE, Tenn., June 29, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced that it is set to join the small-cap Russell 2000® Index and the broad-market Russell 3000® Index...

11 months ago - GlobeNewsWire

Harrow Health (HROW) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.

11 months ago - Zacks Investment Research

SAN DIEGO, June 18, 2020 (GLOBE NEWSWIRE) -- ImprimisRx, the nation’s leading ophthalmic-focused outsourcing facility and pharmaceutical compounding business, a wholly-owned subsidiary of Harrow Healt...

11 months ago - GlobeNewsWire

Harrow Health, Inc. (HROW) CEO Mark Baum on Q1 2020 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Harrow (HROW) delivered earnings and revenue surprises of 0.00% and 16.54%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

ImprimisRx customers will have free access to the entire suite of Doxy.me award-winning telemedicine services ImprimisRx customers will have free access to the entire suite of Doxy.me award-winning tele...

1 year ago - GlobeNewsWire

NASHVILLE, Tenn., March 17, 2020 (GLOBE NEWSWIRE) -- Harrow Health, Inc. (NASDAQ: HROW) today announced the appointment of Teresa Sparks to its Board of Directors.

1 year ago - GlobeNewsWire

Harrow (HROW) delivered earnings and revenue surprises of -23.08% and -10.16%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Harrow Health, Inc. (HROW) CEO Mark Baum on Q4 2019 Results - Earnings Call Transcript

1 year ago - Seeking Alpha

Agreement expands locations served and access to new ImprimisRx formulations Agreement expands locations served and access to new ImprimisRx formulations

1 year ago - GlobeNewsWire

ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery ImprimisRx will supply iOR with a series of unique formulations needed during outpatient surgery

1 year ago - GlobeNewsWire

ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed during ophthalmic surgery ImprimisRx to supply VCNA with a series of surgical pharmaceutical formulations needed du...

1 year ago - GlobeNewsWire

About HROW

Harrow Health, Inc. operates as an ophthalmic-focused healthcare company. The company owns ImprimisRx, an ophthalmology outsourcing and pharmaceutical compounding business; and Visionology, a membership-based online eye health and medication platform. The company also holds equity interests in Surface Ophthalmics, Inc., a clinical-stage pharmaceutical company that focuses on development and commercialization of therapeutics for ocular surface diseases; Melt Pharmaceuticals, Inc., a clinical-stage pharmaceutical company that focused on the devel... [Read more...]

Industry
Drug Manufacturers-Specialty & Generic
Founded
1998
Stock Exchange
NASDAQ
Ticker Symbol
HROW
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 2 analysts, the average rating for Harrow Health stock is "Strong Buy." The 12-month stock price forecast is 15.00, which is an increase of 75.23% from the latest price.

Price Target
$15.00
(75.23% upside)
Analyst Consensus: Strong Buy